| HOME >> MEDICINE >> TECHNOLOGY |
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0Investor Contact:Hayden IR Jeff Stanlis, Partner(602) 476-1821jeff@haydenir.comTables follow
NEWCARDIO, INC(a development stage company) CONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,
December 31,2010
2009(unaudited)ASSETSCurrent assets:Cash
$
,005,320
$
,386,007Short term investment
-
25,010Accounts receivable, trade
86,053
-Prepaid expenses
97,484
111,871Prepaid commitment fees
2,451,754
556,875 Total current assets
3,640,611
2,079,763Property, plant and equipment, net of accumulated depreciation of $138,231 and $79,041 as of September 30, 2010 and December 31, 2009, respectively
173,315
198,955Other assets:Patent costs, net
15,986
-Deposits
22,600
22,600$
3,852,512
$
2,301,318LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities:Accounts payable and accrued expenses
$
482,297
$
480,152Unearned revenue
1,500
-Line of credit
3,000,000
-Put liability
-
744,280 Total current liabilities
3,483,797
1,224,432Warrant liability
1,683,102
1,078,292Reset derivative
-
687,958 Total liabilities
5,166,899
2,990,682Preferred shares subject to liability conversion
-
784,010Stockholders' deficit:Preferred stock, $0.001 par value; 1,000,000 shares authorized:Preferred stock Series B, $0.001 par value; 18,000 shares designated; 12,250 and 16,435 shares issued and outstanding as of September 30, 2010 and December 31, 2009, respectively
12
16Preferred stock Series C, $0.001 par value; 7,000 shares desi
'/>"/>
| SOURCE NewCardio, Inc. Copyright©2010 PR Newswire. All rights reserved |